A large clinical trial of Eli Lilly's experimental Alzheimer's medication, donanemab found the drug slowed declines in patients' ability to think clearly and perform daily tasks by more than a third.
The U.S. Food and Drug Administration has approved LITFULO (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.
The subcutaneous formulation of argenx’s Vyvgart has been approved by the U.S. Food and Drug Administration to treat generalized myasthenia gravis.
The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.
Adding an experimental mRNA-based vaccine developed by Moderna and Merck & Co to Keytruda reduced the risk that melanoma would spread by 65 percent over treatment with the immunotherapy drug alone, according to a midstage trial.
The US Food and Drug Administration has granted fast track designation for Kyverna Therapeutics’ KYV-101 to treat refractory lupus nephritis.
Findings in a recent study suggest that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus.
A new study shows that a protein called glial fibrillary acidic protein is a possible biomarker for very early stages of Alzheimer's.
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
The first clinical trial for Down syndrome regression disorder is being funded by a five-year $5.3 million grant.
